• The relative stereochemistry of both the major and minor

  2024-12-06

  

  The relative stereochemistry of both the major and minor diastereoisomer of (±)-2-(hydroxymethyl)blebbistatin (±)- (and thus (±)-2-(allyloxymethyl)blebbistatin (±)-) was determined with 1D-NOESY experiments (), as crystallization efforts failed. These experiments revealed an interaction between H an

• br Author contributions br Conflicts of interest The authors

  2024-12-06

  

  Author contributions Conflicts of interest The authors declare no competing financial interests. Acknowledgement This work was supported by grants from the Deutsche Forschungsgemeinschaft (Sonderforschungsbereich/Transregio 166–Project C1 and grant CA 1014/1-1 to D.C.) and the IZKF Würzbur

• Mitochondria are key organelles involved

  2024-12-06

  

  Mitochondria are key organelles involved in the mechanism of apoptosis (Xiong et al., 2014), and loss of ΔΨm is an important marker associated with mitochondrial dysfunction and cell death. We found that Mino induced ΔΨm impairment and nuclear fragmentation in Jurkat JWH 133 sale in a concentration

• Once apoptosis has been initiated the HMGA proteins themselv

  2024-12-06

  

  Once apoptosis has been initiated the HMGA proteins themselves undergo marked changes in both the types and extent of their post-translational modifications (PTMs; review in [149,175]), some of which are likely correlated with alterations in chromatin structure. For example, the early stages of apop

• br Conclusions br Funding This work was supported by

  2024-12-06

  

  Conclusions Funding This work was supported by a Finnish government subsidy for health science research [grant numbers TYH2012141, TYH 2013218, and TYH 2014216]; the SSAC Foundation [grant numbers SLS-504141 and SLS-693781]; and the Paulo Foundation. The funding sources had no involvement in s

• Sorafenib was the first small RTK inhibitor drug to

  2024-12-06

  

  Sorafenib was the first small RTK inhibitor drug to be developed and was initially approved against renal cell carcinoma, then against hepatocellular carcinoma (HCC) and more recently for differentiated thyroid treatment [111]. Sunitinib soon followed, being approved for gastrointestinal stromal tum

• ddhGTP While there is much in vivo work

  2024-12-06

  

  While there is much in vivo work on prion-like Aβ, it has not been shown that one can induce inclusions of Aβ in cultured cells as has been shown for tau and α-synuclein. One reason is practical; Aβ is a low molecular weight metabolite cleaved from within the larger amyloid precursor protein (APP) a

• Epiberberine br AMPK as a druggable target AMPK signaling ha

  2024-12-06

  

  AMPK as a druggable target AMPK signaling has attracted considerable attention within the past decades, owing to the capacity of pharmacological compounds (e.g., 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside [AICAR] and metformin) or natural compounds (e.g., resveratrol) to activate AMPK in

• br Disclosure br Acknowledgments br Introduction

  2024-12-05

  

  Disclosure Acknowledgments Introduction Deeper understanding of the pathobiology of non-small cell lung cancer (NSCLC) has led to the development of small Cyclic di-GMP that target genetic mutations known to play critical roles in the progression to metastatic disease. Mutations in epiderm

• In vivo CA mediate hypoxic nutritional and

  2024-12-05

  

  In vivo CA mediate hypoxic, nutritional, and neurologic stress responses. Stimulation of ADRα2A by these hormones to reduce β-cell metabolism has an obvious role in suppressing insulin secretion (Arun, 2004). Since β-cell metabolism and insulin secretion are linked, mechanisms that inhibit metabolis

• inflammation compound screening library br Acknowledgements

  2024-12-05

  

  Acknowledgements Dr. Paul J. Gasser is supported by the National Institutes of Health (grant number R01DA032895), and the Charles E. Kubly Mental Health Research Center. Dr. Christopher A. Lowry is supported by the National Institutes of Health (grant number R21 MH116263), the Department of the N

• br Material and methods br Results br Discussion

  2024-12-05

  

  Material and methods Results Discussion To develop a novel regenerative and/or neuroprotective therapy for optic neuropathy, including glaucoma, numerous studies have tested new candidates favorable to RGC survival and axon regeneration. Among the many candidate drugs, AdoR modulators are o

• Phosphodiesterase inhibition increases the intracellular

  2024-12-02

  

  Phosphodiesterase inhibition increases the intracellular levels of cAMP to restore spontaneous contraction (Essayan, 2001, Qi and Kwan, 1996), acting downstream of adenylyl cyclase. Therefore, cardiac arrest induced by decreased intracellular cAMP levels could be reversed by phosphodiesterase inhibi

• Synthesis pharmacological evaluation for the binding at

  2024-12-02

  

  Synthesis, pharmacological evaluation for the binding at hA, hA and hA ARs, and efficacy at hA subtype of the synthesized compounds, together with the assessment of their theoretical ADME properties were the guidelines in this preliminary drug discovery investigation. The synthetic pathways which y

• br Funding br Introduction The interest in the

  2024-12-02

  

  Funding Introduction The interest in the effects of endocrine disrupting chemicals (EDCs) in the aquatic environment continues to increase over the past decade, specifically those that act on steroidogenic pathways. EDCs that include synthetic androgenic and estrogenic compounds can severely a

15739 records 43/1050 page Previous Next First page 上5页 4142434445 下5页 Last page